An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer
Journal for ImmunoTherapy of Cancer · 2023
DOI: 10.1136/jitc-2022-006274 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2023. Verfasst von Nicole L Wittwer und 5 weiteren Autor:innen. Beteiligte Einrichtung: Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, South Australia, Australia Ni…. Hauptthemen laut MEDLINE: Immunoconjugates, Colonic Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Health Services Charitable Gifts Board, Bristol-Myers Squibb.
Abstract (Originalsprache)
Background
Emerging evidence suggests that the mechanism of chemotherapy-induced cell death may influence the antitumor immune response in patients with cancer. Unlike immunologically silent apoptosis, pyroptosis is a lytic and inflammatory form of programmed cell death characterized by pore formation in the cell membrane and release of proinflammatory factors. Gasdermin E (GSDME) has recently gained attention after cleavage of GSDME by certain chemotherapeutics has been shown to elicit pyroptosis. This study investigated the immunomodulatory effects of a mesothelin-targeting antibody drug conjugate (ADC) in mouse models of breast and colon cancer.
Methods
The antitumor effects of the ADC were studied in EMT6 breast cancer and CT26 colon cancer syngeneic mouse models. The immunomodulatory effects of the ADC were assessed by analysis of tumor-infiltrating immune cells using flow cytometry. ADC mechanism of action was evaluated by morphology, biological assays, ADC-mediated cleavage of key effector proteins, and CRISPR/Cas9-mediated knockout (KO). Finally, the antitumor effect of ADC and Fms-like tyrosine kinase-3 ligand (Flt3L) combination therapy was evaluated in tumors expressing GSDME as well as in GSDME-silenced tumors.
Results
The data demonstrated that the ADC controlled tumor growth and stimulated anticancer immune responses. Investigation of the mechanism of action revealed that tubulysin, the cytotoxic payload of the ADC, induced cleavage of GSDME and elicited pyroptotic cell death in GSDME-expressing cells. Using GSDME KO, we showed that GSDME expression is critical for the effectiveness of the ADC as a monotherapy. Combining the ADC with Flt3L, a cytokine that expands dendritic cells in both lymphoid and non-lymphoid tissues, restored control of GSDME KO tumors.
Conclusions
Together, these results show for the first time that tubulysin and a tubulysin containing ADC can elicit pyroptosis, and that this fiery cell death is critical for antitumor immunity and therapeutic response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, South Australia, Australia Nicole.Wittwer@sa.gov.au.
- Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
- Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology and University of South Australia, Adelaide, South Australia, Australia.
- GPCR Therapeutics USA, Redwood City, California, USA.
- Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
ORCID-Profile: Nicole L Wittwer, Michael P Brown
Förderung
- Health Services Charitable Gifts Board
- Bristol-Myers Squibb
Zitieren
APA
Wittwer, N. L., Staudacher, A. H., Liapis, V., Cardarelli, P., Warren, H., & Brown, M. P. (2023). An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2022-006274
Vancouver
Wittwer NL, Staudacher AH, Liapis V, Cardarelli P, Warren H, Brown MP. An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer. Journal for ImmunoTherapy of Cancer. 2023. doi:10.1136/jitc-2022-006274
BibTeX
@article{Wittwer2023,
author = {Wittwer, Nicole L and Staudacher, Alexander H and Liapis, Vasilios and Cardarelli, Pina and Warren, Harriet and Brown, Michael P},
title = {An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
doi = {10.1136/jitc-2022-006274}
}
EUVIMED